The cannabis withdrawal syndrome: current insights

Area of Science:

• Neuroscience
• Psychiatry
• Addiction Medicine

Background:

• Cannabis withdrawal syndrome (CWS) is a recognized condition linked to cannabis use disorders (CUDs).
• Cessation of long-term, regular cannabis use triggers CWS, characterized by mood and behavioral symptoms.
• Cannabinoid receptor 1 (CB1) downregulation during chronic use reverses during abstinence, potentially defining CWS duration.

Purpose of the Study:

• To review the characteristics, influencing factors, and treatment of cannabis withdrawal syndrome (CWS).
• To discuss the neurobiological underpinnings of CWS, including CB1 receptor changes.
• To highlight the variability in CWS severity and potential treatment avenues.

Main Methods:

• Literature review of animal and human studies on cannabis cessation and withdrawal.
• Analysis of neurobiological mechanisms, including CB1 receptor function.
• Examination of factors influencing CWS severity and treatment outcomes.

Main Results:

• CWS presents with mild to moderate mood and behavioral symptoms, typically manageable in outpatient settings.
• CB1 receptor normalization occurs within 4 weeks of abstinence, suggesting a neurobiological timeframe for CWS.
• CWS severity is influenced by the amount of cannabis used, gender (women report stronger symptoms), and environmental factors.
• Gabapentin and THC analogs show promise for CWS treatment; mirtazapine may help with insomnia.
• Venlafaxine may exacerbate CWS, while other medications have shown limited effects.

Conclusions:

• CWS is a distinct syndrome with variable severity influenced by multiple factors.
• The neurobiological changes in CB1 receptors provide a potential timeframe for withdrawal.
• Further research is needed on treatment settings, psychopharmacological interventions, and behavioral therapies for CWS and long-term CUD prognosis.
• Recommendations include expanding diagnostic criteria for CWS to include physical symptoms and gender effects.